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ABSTRACT
To characterize the costs of allogeneic hematopoietic cell transplantation with high-dose regimens (HDCT), we
analyzed clinical information and costs of 315 HDCT recipients during a 4-year study period beginning in 2000.
Multivariate analyses were performed to identify pre- and/or post-HDCT factors predicting higher costs within
the first year. Overall survival (OS) at 100 days and 1 year were 80% and 58%, respectively. The median cost and
days of hospitalization were $102,574 in 2004 US dollars and 36 days in the hospital for 100 days, and $128,800
and 39 days in the hospital for 1 year. Early costs, defined as costs within the first 100 days, accounted for 84% of
total costs within the first year. Inpatient costs comprise 94% of the early costs, but only 61% of the later costs
defined as costs incurred between 101 days and 1 year.Of the pre-HDCT factors, unrelated donors and advanced
disease risk were significantly associated with increased cost. When post-HDCT events were also considered,
these pre-HDCT factors were no longer independently predictive of high cost. Instead, severe complications
post-HDCT were associated with higher costs, increasing total costs $20,228 on average. If no complications
occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated
and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications.
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Since the first successful allogeneic hematopoietic
cell transplantation (HCT) was performed almost 40
years ago [1], HCT with high-dose regimens
(HDCT, previously called ‘‘myeloablative transplanta-
tion’’) has become an established therapy for patients
with hematological diseases. However, relapse or seri-
ous complications related to HDCT, including graft-
versus-host disease (GVHD), sepsis, cytomegalovirus
(CMV) infection, and fungal infection still limit the
success of the procedure [2-6], and also increase the fi-
nancial cost of HDCT. Indeed, HDCT is recognized
as a very costly procedure, ranging from approximately
$30,000 for an uncomplicated autologous HDCT to$200,000 for an allogeneic HDCT using an unrelated
donor [7]. A 2003 National Health Interview Survey
data showed that 17% of Americans younger than 65
years lack health insurance, and 24% of those 65 years
and older have only Medicare coverage [8]. Few people
can afford HDCT as an out-of-pocket expense. Even
for insured persons, high costs related to HDCT
may limit access to transplantation because of coverage
denial, high deductibles, or lifetime payout caps [9,10].
Therefore, the identification of factors associated with
the high cost of HDCT and the identification of
methods for reducing those costs without compromis-
ing clinical outcomes are of considerable significance.197
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sociated with pre-HDCT characteristics or specific
complications post-HDCT [11-14], and all of these
studies evaluated patients who received HDCT before
2000. Previous studies identified a variety of possible
cost drivers: level of experience of each transplant cen-
ter [15-17]; the health care system[18]; year of trans-
plantation [14]; conditioning regimen or GVHD
prophylaxis [19,20]; changes in diagnostic tools or sup-
portive care [21-23]; clinical outcomes [17]; disease;
disease status; donor characteristics; the graft source;
the age and the health status of recipients; economic
status of each country; governmental economic poli-
cies [14], and others. A number of improvements in
HDCT technology have occurred since 2000. In addi-
tion, patients who previously would have undergone
risky HDCT because of disease indications may in-
stead be receiving HCT with reduced intensity regi-
mens (RIC). There is only one European study
evaluating the treatment cost of severe acute GVHD
(aGVHD) for patients including those transplanted af-
ter 2000 [24]. However, half of the patients in that
study received RIC; characteristics of toxicities and
costs after RICT were considerably different from
those of HDCT, despite similar clinical outcomes
[25]. Thus, we evaluated the cost of HDCT in recent
years. We compared our results with those from pub-
lished literature to determine if recent practice
changes have decreased the cost of HDCT or, at least,
changed the spectrum of cost drivers.
MATERIALS AND METHODS
Study Population
Between June 2000 and July 2004, a total of 376
patients with hematological malignancies received
a HDCT at the Dana-Farber Cancer Institute / Brig-
ham and Women’s Hospital (DFCI/BWH). The anal-
ysis excluded some patients: those who did not receive
high-dose cyclophosphamide and fractionated total
body irradiation (n512); those who received cord
blood grafts (n51) or both bone marrow (BM) and pe-
ripheral blood grafts (n51); and those who had under-
gone allografting previously or, following the index,
HDCT within a year (n510). Patients were also ex-
cluded if nontransplant costs were included in the
hospitalization (n511 with prolonged pre-HDCT
hospital stays for reasons not directly related to their
transplantation) or if cost data were incomplete
(n527). Pre-HDCT characteristics and clinical out-
comes of these excluded patients were similar to those
included in this study (data not shown). A total of 315
patients were included in the analysis.
The Institutional Review Board at the DFCI/
BWH approved these cost studies, and all patients
provided signed, informed consent for their HDCT
procedures.Conditioning Regimen, GVHD Prophylaxis, and
Supportive Care
Conditioning before HDCT consisted of high-
dose cyclophosphamide and fractionated total body
irradiation (TBI) with or without antithymocyte glob-
ulin (ATG). GVHD prophylaxis included cyclospor-
ine or tacrolimus, with or without standard
methotrexate (MTX) (15mg/m2 on day 1, 10mg/m2
on days 3, 6, and 11); tacrolimus, sirolimus, plus low
dose MTX (5mg/m2, days 1, 3, 6, and 11); tacrolimus,
plus sirolimus, without MTX; or T cell depletion
(TCD). Stem cell source was either bone marrow or
granulocyte colony stimulating factor (G-CSF) stimu-
lated peripheral blood stem cells (PBSC). The assign-
ment of conditioning regimen, GVHD prophylaxis,
and/or graft source was based on protocols or clinical
decisions.
The day of graft infusion was designated day 0.
Patients received standard prophylactic acyclovir
from day 5 until 1 year and Pneumocystis jiroveci pro-
phylaxis with atovaquone, dapsone, or trimethoprim-
sulfamethoxazole. Blood was obtained weekly after
engraftment for CMV testing, and patients were
treated pre-emptively with ganciclovir or valgancyclo-
vir if clinically indicated. Levofloxacin was used as bac-
terial prophylaxis if specified by protocol. Patients
were treated with broad spectrum antibiotics at the
time of their first neutropenic fever, and with antifun-
gal agents if applicable.
Patients were admitted to receive their condition-
ing chemotherapy and remained hospitalized until
neutrophil engraftment, adequate oral intake, and an
absence of uncontrolled medical problems. No pa-
tients underwent outpatient transplantation. Patients
were usually provided post-HDCT care at the
DFCI/BWH as described elsewhere [25]. If re-admis-
sion was necessary, they were usually re-admitted to
the DFCI/BWH or transferred to DFCI/BWH
shortly after re-admission at their local hospitals. Pa-
tients continued to be seen at DFCI/BWH through 1
year post-HDCT or until their deaths, even when
also seen outside DFCI/BWH by their referring physi-
cians. At the DFCI, the inpatient unit at the BWH can
deliver intensive care unit (ICU) level care if needed,
including staffing and equipment. In contrast to other
programs, patients are not ‘‘transferred’’ to the ICU.
Clinical Data and Definition
Data regarding baseline patient and transplant char-
acteristics, complications, and relapse occurring within
a year after HDCT were obtained from the clinical
transplant database or patients’ records. The ‘‘early’’
post-transplant phase was defined as being from initial
admission to 100 days after HDCT; the ‘‘later’’ phase
was defined as being from 101 days to 1 year after
HDCT. The early and later phases were examined
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ring within each phase as potential predictors.
1) Disease status. Disease status prior to HDCT
was categorized into two groups. Standard risk was
defined as: acute leukemia in first remission; chronic
myelogenous leukemia (CML) in chronic phase; lym-
phoma in first remission; or refractory anemia without
excess blasts. All other stages and types of hematolog-
ical cancers were considered advanced risk.
2) Complications after HDCT. Neutrophil re-
covery was defined as a neutrophil count of at least
0.5 x 109/L. Early neutrophil engraftment was defined
as engraftment within 15 days after graft infusion.
Platelet recovery was defined as a platelet count of at
least 20 x 109/L. The diagnosis of aGVHD was based
on clinical findings and/or biopsy of the skin, digestive
tract, or liver and graded according to consensus defi-
nition[26]. Chronic GVHD (cGVHD) was also
graded according to previously published criteria[27].
Veno-occlusive disease (VOD) [28], idiopathic pneu-
monia (IP)[29], and diffuse alveolar hemorrhage
(DAH) [30,31] were diagnosed by the attending physi-
cian using clinical criteria. Renal/bladder, neurologi-
cal, or cardiac toxicity were graded according to the
National Cancer Institute common toxicity criteria
with grade 3 or more defined as severe organ toxicity.
Severe infections were captured if patients received an-
tibiotic, antiviral, and/or antifungal agents intrave-
nously regardless of whether or not an organism was
confirmed. In-hospital death was included as a poten-
tial predictor of costs, recognizing that death might be
caused by one of the identified complications. How-
ever, the analysis was repeated excluding in-hospital
death as a potential predictor, and results were similar.
3) Relapse. Relapse was diagnosed based on hema-
tologic parameters, tissue biopsy, bone marrow biopsy
findings, and cytogenetic or molecular methods.
Costs and Hospital Stay
Inpatient costs from admission for HDCT to 1
year post-transplant and outpatient costs during the
same period were obtained from the DFCI/BWH’s ac-
counting system. Inpatient costs include: room costs;
pharmacy; blood bank including stem cell infusion;
laboratory tests; radiation therapy; and miscellaneous
costs. Costs of donor identification and graft procure-
ment were excluded because unrelated donor stem cell
procurement is much more costly than obtaining cells
from family members, and also because we did not
have access to family member graft procurement costs
[32]. In addition, non-medical costs such as caregiver
time, transportation, and local housing costs were
not included because they could not be collected retro-
spectively. We did not capture costs outside of the
DFCI/BWH’s accounting system. Our previous study
documented that external clinic visits and hospital daysoutside of the DFCI/BWH system account for fewer
than 4% of total costs within the first year post-
HDCT [25]. Review of 50% of patients randomly se-
lected from the present study cohort confirmed the
low external costs (outside hospitalization costs/total
costs within a year53.1%). Costs were estimated using
a relative value units methodology [33] within the hos-
pital accounting system, in which costs were calculated
by applying unit costs assigned to each health care ser-
vice item to each patient’s resource utilization. All
costs were adjusted for inflation to the year 2004 using
the medical care component of the consumer price in-
dex [34]. This cost analysis is from the perspective of
the health care system rather than a societal perspec-
tive [35].
Initial hospital stay is defined as the period from
the date of initial admission for conditioning, followed
by graft infusion, to the first date of discharge. Subse-
quent hospitalizations within a year after transplanta-
tion were defined as subsequent hospital stays.
Statistical Analysis
1) Clinical outcomes. Time to post-transplant
events was calculated using the Kaplan-Meier method,
and comparisons were made by using the log-rank tests
[36]. Multivariable logistic regression was used to in-
vestigate risk factors that were associated with devel-
opment of post-transplant events. All analyses were
performed on data collected by January 2006.
2) Evaluation of costs after HDCT. We evaluated
the total cost within the first year and the characteristics
of cost breakdowns by phase after HDCT. To identify
the pre-HDCT factors influencing high costs during
the first year, a multiple linear regression model was
created. The model included all the baseline patient
and transplant characteristics: GVHD prophylaxis; pa-
tient age (.50 years versus [vs] #50 years); donor sex;
donor type; patient and donor cytomegalovirus sero-
logical status; disease (acute lymphoid leukemia vs my-
eloid malignancy vs non-Hodgkin lymphoma [NHL]);
disease status (advanced risk vs standard risk); graft
source; and year of transplantation. To evaluate the im-
pact of clinical events on cost, the presence of specific
post-HDCT complications were included in the
model. These complications were: slow recovery of
neutrophils (neutrophil engraftment after 15 days or
no recovery); morbidity such as VOD, IP/DAH, infec-
tion, more than or equal grade III organ toxicity, such
as renal/bladder toxicity, neurological toxicity and car-
diac toxicity, grade II to IV aGVHD, extensive
cGVHD, and in-hospital death; and relapse during
the first year. Separate analyses of costs were performed
by the phase (ie early or later) after HDCT because
only patients who survived more than 100 days require
later costs. In addition, some complications occurring
in the early phase, such as slow engraftment and
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larly, cGVHD occurring in the later phase should not
contribute to early costs. Also, within the first year after
transplant, all events were ascertained and all surviving
patients included in the early and later phase models.
Thus, our analytical methodology takes into account
the timing of complications when assessing their rela-
tionship to cost.
Because this analytic approach is based on the as-
sumption of a normal distribution of the data, we
used the natural logarithm of the costs and excluded
six patients with extreme outlier costs (.$450,000)
within a year after HDCT to stabilize the variance in
the multivariate analysis. We confirmed the same re-
sults by including these 6 patients. Results are trans-
formed back to their original scale for presentation.
We presented ‘‘incremental costs (IC)’’ and ‘‘ratios’’
in the results section. The IC is the estimated cost dif-
ference in dollars between patients who have a specific
baseline characteristic, experience a specific complica-
tion, or relapse and those who do not. Costs of the two
types of patient groups can be written in the form of
a ratio, which is called the ‘‘ratio.’’ Because of the
high, positive correlation between the days of hospital
stay and costs (r 5 .88, P\ .01), we excluded the days
of hospital stay from the baseline and the full models in
the multivariate analysis.
We investigated all the models that included 2 of
the 9 possible baseline factors and the two-way interac-
tions. Significant interaction terms (P\ .05) were then
included both in the baseline and the full models. All
statistical tests were two-sided. P-values of less than
.01 were considered significant.
RESULTS
Patient and Transplant Characteristics
Patient and transplant characteristics are summa-
rized in Table 1. The median age of patients was 42
years; for donors, the median age was 38 years. Patients
over 50 years are more likely to receive HDCT from
older donors (38% vs 8%, P\ .01). Although MTX
in combination with a calcineurin inhibitor is our
standard GVHD prophylaxis regimen, since 2000, 3
sequential phase II studies have evaluated a siroli-
mus-based regimen [37-39]. In addition, patients
who underwent transplantation earlier were more
likely to have bone marrow (BM) grafts (P\ .01). As
a result, patients receiving MTX in their GVHD pro-
phylactic regimen were more likely to undergo trans-
plantation in earlier years (P\ .01) and to have BM
grafts than those who did not receive MTX (BM graft;
standard dose MTX vs low-dose MTX vs no MTX:
64% vs 73% vs 18%, P\ .01). Patients who received
low-dose MTX as a GVHD prophylaxis on a research
protocol were more likely to have HLA mismatcheddonors (standard dose MTX vs low-dose MTX vs no
MTX: 14% vs 30% vs 2%, P\ .01) and underwent
transplantation before 2003. Median follow-up of all
patients was 426 (interquartile range (IQR), 127-
1062) days. Median follow-up of surviving patients
was 1096 (IQR 741-1433) days.
Table 1. Patient and transplantation characteristics
Variables
N (%) [Interquartile
range]
Number of patients 315
Patients’ age, median years 42 [33-48]
Donors’ age, median years 38 [29-45]
Donor sex
Male 184 (58)
Female 131 (42)
HLA matching
Matched 273 (87)
Mismatched 42 (13)
Patient-donor relationship
Related donor 158 (50)
Unrelated donor 157 (50)
CMV serological status
CMV positive donor and/or patient 170 (54)
CMV negative donor and patient 145 (46)
Disease
ALL 44 (14)
AML 107 (34)
MDS 45 (14)
CML 64 (20)
NHL 37 (12)
Other* 18 (6)
Disease status†
standard risk 108 (34)
advanced risk 207 (66)
Stem cell source
bone marrow 152 (48)
peripheral blood 163 (52)
GVHD prophylaxis
Cyclosporine or Tacrolimus with MTX 107 (34)
Cyclosporine or Tacrolimus without MTX 5 (2)
Tacrolimus with Sirolimus 60 (19)
Tacrolimus, Sirolimus, and MTX 82 (26)
TCD 61 (19)
Year of transplant
2000 59 (19)
2001 87 (28)
2002 79 (25)
2003 72 (23)
2004 18 (6)
Days of median follow-up 426 [127-1062]
ALL indicates acute lymphoblastic leukemia; AML, acute myeloge-
nous leukemia; MDS, myelodysplastic syndrome; CML, chronic
myelogenous leukemia; NHL, non-Hodgkin lymphoma; GVHD,
graft-versus-host disease; MTX, methotrexate; TCD, T cell
depleted transplantation
*Others include chronic lymphoblastic leukemia, Hodgkin lym-
phoma, multiple myeloma, and other leukemia
†Standard disease risk was defined as: acute leukemia in first remis-
sion, chronic myelogenous leukemia in chronic phase, lymphoma in
first remission, or refractory anemia without excess blasts. All other
stages and types of hematological cancers were considered advanced
disease risk.
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Table 2 summarizes aggregate clinical outcomes
within the first year after HDCT. In the early phase,
unrelated donor recipients experienced more compli-
cations including VOD (15% vs 8%), IP/DAH (15%
vs 6%), severe infection (44% vs 28%), severe renal/
bladder toxicity (19% vs 6%), severe neurological tox-
icity (15% vs 7%), and in-hospital death (22% vs
11%). Incidence of grade II to IV aGVHD (unrelated
vs related: 39% vs 32%, P5.18) and relapse rate (unre-
lated vs related: 7% vs 11%, P5 .60) did not differ be-
tween related and unrelated donor transplantation in
the early phase. In the later phase, incidence of
cGVHD for unrelated donor recipients was higher
(70% vs 57%, P5.04), but that of extensive cGVHD
(unrelated vs related: 53% vs 42%, P5.09), incidence
of other post-HDCT complications and rate of relapse
were similar between the two groups. Consequently,
unrelated donor recipients had lower disease-free sur-
vival (DFS) and overall survival (OS) at 100 days and 1
year (DFS: 68% vs 82% at 100 days, 48% vs 59% at 1
year, P 5 .02; OS: 73% vs 87% at 100 days, 52% vs
64% at 1 year, P\ .01). Several clinical factors were
found to be associated with the development of com-
Table 2. Clinical outcomes
Variables
Early phase
N (%)
Later phase
N (%)
Number of evaluated patients 315 252
Post-transplant events
Neutrophil engraftment
($0.5x109/L), median days
[interquartile range]
15 [13-18] -
Platelet engraftment
($2.0x109/L), median days
[interquartile range]
25 [16-44] -
Veno-occlusive disease 35 (11) -
Idiopathic pneumonia / diffuse
alveolar hemorrhage
33 (11) 10 (4)
Infection ($grade 3) 110 (35) 66 (26)
Viral 38 (12) 29 (12)
Bacterial 79 (25) 35 (14)
Fungal 26 (8) 13 (5)
Renal/bladder toxicity ($grade 3) 48 (15) 23 (9)
Cardiac toxicity ($grade 3) 22 (7) 19 (8)
Neurological toxicity ($grade 3) 35 (11) 22 (9)
In-hospital death 53 (17) 45 (18)
Grade II-IV aGVHD
in the early phase
112 (35) -
Extensive cGVHD
in the later phase
- 119 (47)
Relapse 25 (8) 37 (15)
Disease-free survival at 100 days
or at 1 year
75±2 % 53±3 %
Overall survival at 100 days
or at 1 year
80±2 % 58±3 %
Early phase indicates initial admission through 100 days after trans-
plantation; later phase, from 101 days to 1 year (365 days) after
transplantation; GVHD, graft-versus-host disease; aGVHD,
acute GVHD; cGVHD, chronic GVHD.plications. Minimization of MTX in the GVHD pro-
phylactic regimen (no MTX, odds ratio (OR)50.47,
P\ .01; low MTX, OR5.06, P 5 .03) and use of pe-
ripheral blood as the stem cell source (OR5.17, P\
.01) were associated with early recovery of neutrophils.
Patient age greater than 50 years was associated with
later neutrophil recovery (OR52.70, P 5 .01) and
higher occurrence of IP/DAH (OR52.30, P 5 .04).
A positive CMV serology in donor or patient was asso-
ciated with an increased risk of VOD (OR52.77, P 5
.01). Grade II to IV aGVHD was associated with less
relapse, both throughout the entire follow-up period
(OR50.58, P5 .05) and when the analysis was limited
to patients surviving more than a year (OR50.39, P5
.02). Prior grade II to IV aGVHD was also associated
with extensive cGVHD in the later phase (OR52.37,
P \ .01). Advanced risk disease was associated with
a higher relapse rate both in the early phase
(OR52.32, P 5 .08) and in the later phase (OR52.51,
P5 .04).
Costs and Days of Hospital Stay
Univariate results for costs and days of hospital
stay are shown in Table 3. The median total costs
within 100 days and 1 year after HDCT were
$102,574 and $128,800, respectively. Initial hospitali-
zation costs accounted for 79% of total costs in the
early phase post-HDCT, and costs of the early phase
accounted for 84% of all costs within the first year.
Breakdown analyses of cost categories by post-trans-
plant phase are shown in Figure 1A. In the early phase,
inpatient costs were 94% of total costs; in the later
phase, they accounted for 61% of total costs. Room
costs were the largest category of costs, followed by
pharmacy and blood bank, accounting for 76% of total
costs in the early phase. Outpatient costs accounted for
6%, on average, in the early post-transplant period, in-
creasing from 2.0% in 2000 to 7.1% in 2004. Similar
patterns of cost distribution were seen regardless of
Table 3. Univariate analyses of costs and days of hospital stay
Variables Median
Interquartile
range
Total cost, 2004 $
Total cost within the first 100 days 102,574 78,679-161,990
Total cost of the first year 128,800 90,511-194,030
Inpatient cost, 2004 $
Inpatient cost within the first
100 days
96,264 71,090-150,293
Total inpatient cost of the first year 110,082 77,057-175,348
Outpatient cost, 2004 $
Outpatient costs within the first
100 days
4,589 403-10,476
Total outpatient costs of the first year 10,493 558-23,397
Hospital stay, days
Hospital stay for the first 100 days 36 28-47
Total hospital stay for the first year 39 30-54
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of complications.
The changes in total costs during the first year
post-HDCT by year of transplant were shown in
Figure 1B. Both cost and days of hospital stay in-
creased from 2000 to 2002, but both decreased from
2002 to 2004. One-year DFS for patients transplanted
in each year improved steadily (46% in 2000 and 78%
in 2004).
The results of the multivariate analyses of costs for
the first year are shown in Table 4. For example, a ratio
of 1.3 for costs corresponds to a 30% increase in costs
(IC $35,042) when patients transplanted from unre-
lated donors are compared with those transplanted
from related donors, controlling for all other variables
(P\ .01). Advanced risk diseases (IC $20,109, ratio
1.2, P 5 .04) were also associated with higher costs.
Patients transplanted from female donors also had
higher costs. However, there was an interaction with
patient age such that the effect of donor sex was seen
specifically in patients who were aged over 50 years
(IC $38,960, ratio 1.5, P 5 .02). In the full model of
early costs, considering both the baseline variables
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Figure 1. Characteristics of costs during the first year. (A) Propor-
tion of costs by phase after transplantation. Abbreviation: early
phase, initial admission through 100 days after transplantation; later
phase, from 101 days to 1 year (365 days) after transplantation. (B)
Relationship between total costs and disease-free survival during
the first year by each year of transplantation. Boxes indicate the me-
dian costs in 2004 dollars within the first year post-HDCT. Lines in-
dicate the disease-free survival at 1 year. Numbers of patients in each
transplant year are shown in the parentheses.and post-transplant events occurring within the first
100 days, the following were the independent factors
associated with high costs: grade II to IV aGVHD
(IC $46,414, ratio 1.3, P\ .01); late neutrophil recov-
ery or without engraftment (IC $48,789, ratio 1.3, P\
.01); VOD (IC $53,009, ratio 1.3, P\ .01); IP/DAH
(IC $40,741, ratio 1.2, P\ .01); severe neurological
toxicity (IC $43,639, ratio 1.2, P\ .01) and in-hospital
death (IC $50,476, ratio 1.3, P\ .01). Severe infection
(IC $17,553, ratio 1.1, P 5 .06), severe renal/bladder
toxicity (IC $26,775, ratio 1.1, P 5 .08), and severe
cardiac toxicity (IC $33,256, ratio 1.2, P 5 .07) were
also found to be marginal predictors of high costs. Re-
lapse in the early phase was not associated with higher
costs. In the full model limited to patients who sur-
vived over 100 days, higher later costs were associated
with extensive cGVHD (IC $7,003, ratio 1.7, P\ .01),
relapse (IC $15,069, ratio 2.9, P\ .01), and in-hospi-
tal death (IC $23,435, ratio 4.7, P\ .01) after control-
ling for the baseline variables and post-transplant
events. Use of unrelated donors remained marginally
predictive of high costs in the early phase (IC
$19,341, ratio 1.1, P 5 .09) and in the later phase
(IC $6,244, ratio 1.6, P 5 .05) in the full model.
Given the different clinical outcomes between re-
lated and unrelated donor transplantations, we per-
formed a stratified analysis of donor type and
confirmed the same results. In-hospital death was asso-
ciated with the diagnosis of VOD, but not other com-
plications in the early phase. In the later phase, patients
with severe neurological, renal/bladder, or cardiac tox-
icities were more likely to die in the hospital. Exclusion
of in-hospital death as a potential predictor would
increase the IC of complications by $1,716-$22,253,
except for neurological toxicity where the IC would
decrease by $299 in the early phase. Exclusion of in-
hospital death as a predictor of later costs would
change the ICs between -$6,265 and $11,570.
When the total number of complications was con-
sidered, cost increased $20,228 on average per compli-
cation. OS at 1 year decreased with each additional
complication with a particularly steep drop-off if 3
or more complications occurred (Figure 2A). If no
complications occurred, costs during the first year
were $79,222, consisting of $74,044 in the early phase,
plus $6,080 in the later phase, after controlling for all
the baseline characteristics as well as number of com-
plications. Figure 2B compares the costs of patients
dying in the early phase (n563), those dying in the
later phase (n570), and surviving patients (n5182)
throughout the first year post-HDCT. Surviving pa-
tients were the least costly (P \ .01), whereas costs
of patients dying within the first year were similar re-
gardless of whether death occurred in the early or later
phase (P5 .53). Sixty-one percent of deceased patients
accrued costs over $150,000 per patient, whereas 26%
of surviving patients had costs above that amount.
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Baseline model
Full model
(early phase)
Full model
(later phase)
Variables*
Incremental
costs
Ratio
(95% CI) P-value
Incremental
costs
Ratio
(95% CI) P-value
Incremental
costs
Ratio
(95% CI) P-value
GVHD
prophylaxis
Low dose MTX vs Standard dose MTX -19,573 0.9 (0.7-1.0) 0.12 6,971 1.0 (0.9-1.2) 0.58 -7,347 0.6 (0.4-1.0) 0.05
No MTX vs Standard dose MTX -14,282 0.9 (0.7-1.1) 0.34 -3,246 0.9 (0.8-1.1) 0.55 1,572 1.1 (0.6-2.0) 0.70
TCD vs Non TCD -3,734 1.0 (0.8-1.2) 0.80 -8,753 1.0 (0.8-1.2) 0.85 2,504 1.2 (0.7-2.2) 0.54
HLA matching
Mismatched vs Matched 5,561 1.0 (0.8-1.3) 0.70 11,218 1.1 (0.9-1.2) 0.42 2,047 1.2 (0.6-2.1) 0.62
Donor type
Unrelated vs Related 35,043 1.3 (1.1-1.5) \0.01 19,341 1.1 (1.0-1.2) 0.09 6,244 1.6 (1.0-2.5) 0.05
Disease
ALL vs Myeloid -17,995 0.9 (0.7-1.1) 0.17 14,756 1.1 (0.9-1.2) 0.25 -6,788 0.6 (0.4-1.0) 0.06
NHL vs Myeloid -7,474 0.9 (0.8-1.2) 0.58 8,873 1.0 (0.9-1.2) 0.51 1,854 1.1 (0.7-1.9) 0.60
Disease Status
Advanced risk vs Standard risk 20,109 1.2 (1.0-1.3) 0.04 7,970 1.0 (0.9-1.1) 0.41 907 1.1 (0.7-1.5) 0.72
Donor sex
Female donor vs Male donor 24,027 1.2 (1.0-1.4) 0.04 16,406 1.1 (1.0-1.2) 0.14 2,132 1.2 (0.7-1.8) 0.50
Patient age
Aged 51 or older vs Aged 50
or younger
1,071 1.0 (0.9-1.2) 0.93 10,396 1.0 (0.9-1.2) 0.34 917 1.1 (0.7-1.7) 0.77
Stem cell source
Bone marrow vs Peripheral blood -1,669 1.0 (0.8-1.2) 0.89 -11,994 0.9 (0.8-1.1) 0.35 -3,911 0.8 (0.5-1.2) 0.24
CMV serological status
CMV positive vs CMV negative 15,015 1.1 (1.0-1.3) 0.08 11,929 1.1 (1.0-1.2) 0.17 1,255 1.1 (0.8-1.5) 0.59
Year of transplant
2000 vs 2004 -13,055 0.9 (0.6-1.3) 0.59 -47,244 0.8 (0.6-1.0) 0.06 -19,457 0.3 (0.1-0.7) \0.01
2001 vs 2004 12,292 1.1 (0.8-1.6) 0.60 -24,599 0.9 (0.7-1.1) 0.30 -4,707 0.7 (0.3-1.7) 0.45
2002 vs 2004 30,231 1.3 (0.9-1.7) 0.15 19,088 1.1 (0.9-1.4) 0.38 -5,272 0.7 (0.3-1.5) 0.32
2003 vs 2004 22,124 1.2 (0.9-1.6) 0.28 513 1.0 (0.8-1.2) 0.98 1,593 1.1 (0.5-2.4) 0.76
Recovery of neutrophil
Late or without recovery vs
Early recovery
48,789 1.3 (1.1-1.4) \0.01 - - -
VOD
Yes vs No 53,009 1.3 (1.1-1.5) \0.01 - - -
IP/DAH
Yes vs No 40,741 1.2 (1.1-1.4) \0.01 7,006 1.7 (0.7-4.0) 0.26
Infection
Yes vs No 17,553 1.1 (1.0-1.2) 0.06 4,186 1.4 (0.9-2.0) 0.14
Renal/bladder toxicity
Yes vs No 26,775 1.1 (1.0-1.3) 0.08 5,242 1.5 (0.8-2.6) 0.19
Neurological toxicity
Yes vs No 43,639 1.2 (1.1-1.4) \0.01 6,989 1.7 (0.9-3.2) 0.13
Cardiac toxicity
Yes vs No 33,256 1.2 (1.0-1.4) 0.07 5,566 1.5 (0.8-2.8) 0.24
Grade II to IV acute GVHD
Yes vs No 46,414 1.3 (1.1-1.4) \0.01 - - -
extensive chronic GVHD
Yes vs No - - - 7,003 1.7 (1.2-2.3) \0.01
Relapse
Yes vs No 17,890 1.1 (0.9-1.3) 0.26 15,069 2.9 (1.7-4.9) \0.01
In-hospital death
Yes vs No 50,476 1.3 (1.1-1.5) \0.01 23,435 4.7 (2.7-8.1) \0.01
CI indicates confidence interval; early phase, initial admission through 100 days after transplantation; later phase, from 101 days to 1 year (365 days) after
transplantation; GVHD, graft-versus-host disease; MTX, methotrexate; vs, versus; TCD, T cell depleted; ALL, acute lymphoblastic leukemia;
AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CML, chronicmyelogenous leukemia;NHL, non-Hodgkin lymphoma; my-
elogenous included AML, MDS, and CML; CMV, cytomegalovirus; CMV positive, CMV positive serology in either donor or patient; CMV neg-
ative, CMV negative serology both in patient and donor; late or without recovery, late or without neutrophil engraftment; early recovery, early
neutrophil engraftment within 15 days after HCT; VOD, veno-occlusive disease; IP, idiopathic pneumonia; DAH, diffuse alveolar hemorrhage.
*Reference groups: standard dose MTX, TCD, HLA matched, related, myeloid, standard risk, male donor, aged 50 years or younger, peripheral
blood, CMV negative, patients transplanted in 2004, patients with early recovery, no VOD, no IP/DAH, no infection, no renal/bladder toxicity,
no neurological toxicity, no grade II to IV acute GVHD, no extensive chronic GVHD, did not relapse, did not die in the hospital.
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In accordance with the previous literature
[19,20,32,40,41], our data showed that the costs within
the first 100 days (median $102,574) made up a sub-
stantial portion of the total costs within the first year
for HDCT. This pattern of cost accrual differs from
solid organ transplantation such as lung transplants,
where long-term costs tend to be higher than initial
or early costs [42-44]. Advances in stem cell transplant
techniques, supportive care, and the recent change of
primary locus of care for HDCT from inpatient to
outpatient are anticipated to reduce costs especially
for low-risk patients [45], hopefully without increasing
long-term costs. Our data showed that although there
was a trend towards increased outpatient costs since
A
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Figure 2. Relationship between costs and post-transplant events or
death. (A) Costs and overall survival during the first year after trans-
plantation by number of complications. Boxes indicate the estimated
mean costs in 2004 dollars for the first year after transplantation,
which were adjusted for patient and transplant characteristics and
the 95% confidence interval were shown by the full range of upper
and lower whiskers. Lines indicate the overall survival at 1 year.
Late neutrophil recovery, veno-occlusive disease, idiopathic pneu-
monia/diffuse alveolar hemorrhage, severe infection, severe renal/
bladder toxicity ($grade 3), severe neurological toxicity ($grade
3), severe cardiac toxicity ($grade 3), grade II to IV acute GVHD,
extensive chronic GVHD, relapse, and in-hospital death during
the first year were considered. Numbers of patients with each num-
ber of complications are shown in the parentheses. (B) Costs during
the first year after transplantation for deceased or surviving patients.2002, these costs still comprise a small proportion of
total costs within the first year at our institution.
In contrast to the previous finding by Bennett et al
[17], but in agreement with Griffith et al , good clinical
outcomes do not necessarily translate into lower costs
and fewer days of hospital stay in our study. During the
period of this study, our institution studied ‘‘low dose
MTX’’ or ‘‘sirolimus based, without MTX’’ regimens.
Costs during this period rose coincident with these
studies [46], but then later fell, whereas DFS improved
steadily. This non-linear change in costs over time was
still detected in the multivariate analysis. Once physi-
cians and support staff gain additional experience
with the new GVHD prophylaxis regimens, treatment
approaches, supportive care, and/or patient selection
criteria we speculate this may result in both better out-
comes and reduced costs for the last two years of the
study period, as demonstrated by Freeman et al [16].
One concern about cost analyses of procedures
with appreciable mortality rates is low costs may be
seen if patients either die very early or have uncompli-
cated courses, two very different clinical outcomes.
Our data showed that deceased patients were more
costly compared to surviving patients even when they
died in the early phase post-HDCT.
Although we expected complications to lead to
higher costs, it is difficult to determine estimates of
these effects from the literature. In multivariate analy-
sis considering only pre-HDCT factors (those known
as a patient starts HDCT), use of an unrelated donor
[12-14] and advanced risk diseases were the significant
predictors of high costs. When both pre- and post-
HDCT factors were included in the model, post-
HDCT complications, such as grade II to IV aGVHD,
late neutrophil recovery or without engraftment,
VOD, IP/DAH, severe neurological toxicity, and in-
hospital death were associated with higher costs of be-
tween $40,741 and $53,009 within the first 100 days. If
patients experienced extensive cGVHD, relapse, and
in-hospital death beyond 100 days, costs of between
$7,003 and $23,435 were added in the later time pe-
riod. Our study showed a positive correlation between
the development of grade II to IV aGVHD and
decreased relapse rate if patients survive longer. De-
spite high costs associated with some complications,
patients may ultimately experience clinical benefit in
the long term.
We found the estimated costs were $79,222 (n515)
for the first year if no complication occurred; this was
lower than similar estimates of costs of ‘‘uncomplicated
patients’’ who received transplants before 2000, report-
edly $119,096 for the initial hospitalization[12] and
$109,594 for 5 years post-transplant [41] (Table 5).
(All dollar values were converted to 2004 US dollars us-
ing the consumer price index for more effective com-
parison). These findings suggest a possible trend of
cost reduction for uncomplicated cases transplanted
Table
Public
acute
GVHD
chronic
GVHD
Mean (median)
cost per patient
Mean (median)
hospital days
Griffit
199
$88,573 1$72,451 $396,978
($334,076)
Lee
200
$37,143 ($139,188)
Esper
200
0-1 vs $
G2:1 $26,839
1$32,952 $112,659
($102,727)
initial
hospitalization
34 (33)
Svahn
200
R51.35† initial
hospitalization:
($54,967) 1y:
($126,065 ipt. 1
$16,366 opt.)
5y: ($142,347 ipt.
1 $27,738
opt. 5 $174,617
total)‡
Saito[ $46,414 1$7,003 ($102,574) (36)
($128,800)
All do e; GVHD, graft-versus-host disease; Allo-, allogeneic; BMT, bone
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Cost of complication,
mean (median)
ation
Type of
transplant Disease
Time
horizons
uncomplicated
transplant
costs Infection
CMV
infection VOD
hs
3[14]
Allo-BMT
’80-’87
409 malignant
or nonmalignant
disease
6 months
(payer costs,
ipt. costs only)
1$101,939 1
0[12]
Allo-HCT
’94-’97
181 hematological
malignancy
initial
hospitalization
$119,096 1$20,224 1$24,586 1
ou
4[13]
Allo-HCT
MCRCT
’98-’00
85 (RCT:200)
hematological
malignancy
6 months 0-2 vs $3: 1$17,010 1$5,358 G
6[41]
Allo-HCT ’
98-’99
93 malignant
or nonmalignant
disease,
solid tumor
5 years $109,594*‡ RR51.33† RR51.32† R
25] Allo-HCT
’00-’04
315 hematological
malignancy
early phase $74,044 1$17,553 1$53,009 1
later phase $6,080
llar values were converted to 2004 dollars for more effective comparison. CMV, cytomegalovirus; VOD, veno-occlusive diseas
arrow transplantation; HCT, hematopoietic cell transplantation; RCT, randomized clinical trial; G, grade; RR, relative risk; d,
mission to 100 days after transplantation; later phase, from 101 days to 1 year (365 days) after transplantation.
were read from Figure 2 in the paper.
al incremental costs over the baseline were not described in the paper. The ratios that appeared in the table were derived from a m
$1.3
206 A. M. Saito et al.recently. On the other hand, compared to the published
literature, costs for infection or grade II to IV aGVHD
have not changed significantly over time, but costs of
VOD may be higher for patients who received trans-
plant recently. Expensive supportive care may improve
outcomes and increase cost.
Although results are derived from a single center
study, the size of the study population with the same
conditioning regimens and the 4-year period of study
help mitigate concerns of generalizability. Our results
can be used to project the financial implications of dif-
ferent complications, and to model effects of different
approaches to prophylaxis. We could not capture costs
accrued beyond the first year post-HDCT, however
we believe longer follow-up is not necessary to esti-
mate the cost implications of pre-transplant factors
and early complications [41]. Most economic studies
analyze costs because costs are true measures of re-
sources used. In contrast, charges are usually multiple
of costs and are driven by many local factors varying
from institution to institution. Charges may be com-
puted from costs using departmental ratios of costs
to charges in each institution.
In conclusion, we found that costs for the first 100
days were the major cost contributors during the first
year after transplantation, and inpatient costs ac-
counted for the majority of the total costs. Use of un-
related donors and advanced disease status predict
higher costs when considering only pre-HDCT fac-
tors. When post-HDCT events are considered, severe
complications appear to be major cost driver with an
average incremental cost of $20,228. If complications
can be prevented or be treated by less costly, but effec-
tive procedures, significant cost savings might be
achieved, along with better clinical outcomes.
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